癌症治疗的未来：选择可能对PD1/L1阻断疗法有反应的患者。
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade.
作者信息
Ribas Antoni, Tumeh Paul C
机构信息
Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. Department of Surgery, University of California Los Angeles, Los Angeles, California. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.
Division of Dermatology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
出版信息
Clin Cancer Res. 2014 Oct 1;20(19):4982-4. doi: 10.1158/1078-0432.CCR-14-0933. Epub 2014 Jun 26.
Abstract
It is conceivable that, in the near future, an assay that defines the likelihood of a patient with advanced cancer to respond to immunotherapy based on PD1/L1 blockade will be the initial decision point to select the treatment of patients with any cancer type.
摘要
可以想象，在不久的将来，一种基于PD1/L1阻断来确定晚期癌症患者对免疫疗法反应可能性的检测方法，将成为选择任何癌症类型患者治疗方案的初始决策点。
相似文献
1
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade.癌症治疗的未来：选择可能对PD1/L1阻断疗法有反应的患者。
Clin Cancer Res. 2014 Oct 1;20(19):4982-4. doi: 10.1158/1078-0432.CCR-14-0933. Epub 2014 Jun 26.
2
[Not Available].[无可用内容]。
Bull Cancer. 2018 Dec;105 Suppl 1:S101-S112. doi: 10.1016/S0007-4551(18)30395-3.
3
4
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.预测生物标志物和抗 PD1/PD-L1 阻断癌症免疫治疗的机制。
Mol Cancer. 2020 Jan 30;19(1):19. doi: 10.1186/s12943-020-1144-6.
5
The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.PD-L1检测在选择非小细胞肺癌患者进行PD1/PD-L1导向治疗中的临床应用。
Clin Pharmacol Ther. 2016 Sep;100(3):212-4. doi: 10.1002/cpt.385. Epub 2016 Jun 3.
6
Mechanisms of Resistance to PD-1 and PD-L1 Blockade.对PD-1和PD-L1阻断的耐药机制。
Cancer J. 2018 Jan/Feb;24(1):47-53. doi: 10.1097/PPO.0000000000000303.
7
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.靶向细胞程序性死亡受体 1（PD-1）及其配体（PD-L1）：癌症主动免疫治疗的新纪元。
Pharmacol Ther. 2019 Feb;194:84-106. doi: 10.1016/j.pharmthera.2018.09.008. Epub 2018 Sep 28.
8
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
9
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).在研究免疫检查点阻滞剂（PD-1/PD-L1抑制剂）的早期临床试验中，不应将基线淋巴细胞减少用作排除标准。
Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18.
10
PDL-1/PD1 inhibitors: antibody or antinobody?程序性死亡受体配体1/程序性死亡蛋白1抑制剂：抗体还是抗抗体？
Future Oncol. 2017 Aug;13(19):1669-1671. doi: 10.2217/fon-2017-0215. Epub 2017 Aug 23.
引用本文的文献
1
Neoadjuvant therapy and surgical resection successfully treating primary thyroid squamous cell carcinoma: a case report.新辅助治疗与手术切除成功治疗原发性甲状腺鳞状细胞癌：一例报告
Gland Surg. 2025 Jul 31;14(7):1399-1405. doi: 10.21037/gs-2025-88. Epub 2025 Jul 28.
2
Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer.乳酰化预后特征将DHCR7鉴定为膀胱癌化疗耐药和免疫治疗疗效的调节因子。
Front Immunol. 2025 Jul 15;16:1585727. doi: 10.3389/fimmu.2025.1585727. eCollection 2025.
3
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker.黑色素瘤中 HLA-DR 的表达：从误导性的治疗靶点到潜在的免疫治疗生物标志物。
Front Immunol. 2024 Jan 17;14:1285895. doi: 10.3389/fimmu.2023.1285895. eCollection 2023.
4
Clinicopathological Features and Status of Programmed Death Ligand-1 (PD-L1) Expression in Lung Cancer: A Single Centre Study From North India.肺癌中程序性死亡配体-1（PD-L1）表达的临床病理特征及状态：来自印度北部的一项单中心研究
Cureus. 2023 Feb 16;15(2):e35056. doi: 10.7759/cureus.35056. eCollection 2023 Feb.
5
PDJ amplicon in triple negative breast cancer.三阴性乳腺癌中的 PDJ 扩增子。
Sci Rep. 2023 Jan 12;13(1):618. doi: 10.1038/s41598-023-27887-8.
6
Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience.肺癌中三种 PD-L1 克隆的表达：单中心经验。
In Vivo. 2023 Jan-Feb;37(1):233-241. doi: 10.21873/invivo.13072.
7
A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.一种新型 TGF-β 风险评分可预测膀胱癌的临床结局和肿瘤微环境表型。
Front Immunol. 2021 Dec 17;12:791924. doi: 10.3389/fimmu.2021.791924. eCollection 2021.
8
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.免疫细胞图谱预测 PD-1 阻断治疗皮肤 T 细胞淋巴瘤的反应。
Nat Commun. 2021 Nov 18;12(1):6726. doi: 10.1038/s41467-021-26974-6.
9
N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.N6-甲基腺苷相关长链非编码RNA预测膀胱癌的预后和免疫治疗反应
Front Oncol. 2021 Aug 11;11:710767. doi: 10.3389/fonc.2021.710767. eCollection 2021.
10
Molecular Targeted Agent and Immune Checkpoint Inhibitor Co-Loaded Thermosensitive Hydrogel for Synergistic Therapy of Rectal Cancer.用于直肠癌协同治疗的分子靶向药物与免疫检查点抑制剂共载热敏水凝胶
Front Pharmacol. 2021 Apr 16;12:671611. doi: 10.3389/fphar.2021.671611. eCollection 2021.
本文引用的文献
1
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.程序性死亡受体-1（PD-1）、PD-1配体与肿瘤免疫微环境的其他特征与抗PD-1治疗反应的相关性
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.
2
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.纳武利尤单抗治疗晚期黑色素瘤患者的生存、持久肿瘤缓解和长期安全性。
J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3.
3
Digital genomic quantification of tumor-infiltrating lymphocytes.肿瘤浸润淋巴细胞的数字基因组定量
Sci Transl Med. 2013 Dec 4;5(214):214ra169. doi: 10.1126/scitranslmed.3007247.
4
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
5
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.拉罗替尼（anti-PD-1）治疗黑色素瘤的安全性和肿瘤应答。
N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.
6
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
7
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
8
Tumor immunotherapy directed at PD-1.针对程序性死亡受体1（PD-1）的肿瘤免疫疗法。
N Engl J Med. 2012 Jun 28;366(26):2517-9. doi: 10.1056/NEJMe1205943. Epub 2012 Jun 2.
9
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.在人类黑色素病变中，炎症反应与 B7-h1 表达的共定位支持了免疫逃避的适应性抵抗机制。
Sci Transl Med. 2012 Mar 28;4(127):127ra37. doi: 10.1126/scitranslmed.3003689.
10
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
Zotero 插件